Itron (ITRI) Tops Q4 EPS by 63c, Offers Guidance

Itron (NASDAQ: ITRI) reported Q4 EPS of $0.71, $0.63 better than the analyst estimate of $0.08. Revenue for the quarter came in at $467 million versus the consensus estimate of $433.64 million.

GUIDANCE:

Itron sees FY2023 EPS of $0.70-$1.10, versus the consensus of $1.53. Itron sees FY2023 revenue of $1.85-1.95 billion, versus the consensus of $1.88 billion.

Itron sees Q1 2023 EPS of $0.05-$0.15, versus the consensus of $0.21. Itron sees Q1 2023 revenue of $460-475 million, versus the consensus of $451 million.

For earnings history and earnings-related data on Itron (ITRI) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Workhorse Group (WKHS) Misses Q2 EPS by 77c
• Bio-key International, Inc. (BKYI) Tops Q2 EPS by 24c